Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733091 · ClinicalTrials.gov registry record
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
A clinical trial of Tumors, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT05733091: Recruiting study of Tumors, sponsored by M.D. Anderson Cancer Center.
NCT05733091 is a study of Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants, above the 184-participant average among 20 other Tumors trials with a reported enrollment target (63% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733091, a study of Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer
Primary Outcome
MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) is a disease specific PRO instrument validated for patients with head and neck cancer. It is the most commonly utilized instrument in the head and neck cancer population, of which sinonasal and nasopharyngeal tumors are disease subsites. Score scale from 0 (symptom has been present) to 10 (the symptom was as bad as you can imagine it could be)
Conditions Studied
Interventions
- BEHAVIORAL Standard of Care
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2029-12-31 |
What NCT05733091 shows while recruiting
NCT05733091 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 20 other Tumors trials with a reported enrollment target (63% higher).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care is the first listed.
NCT05733091 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05733091 about?
NCT05733091 is a clinical study titled "Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors". To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer
What is the current status of trial NCT05733091?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2018-12-20. Estimated completion is 2029-12-31.
What conditions does trial NCT05733091 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT05733091?
The interventions under investigation include: Standard of Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT05733091?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733091 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05733091's enrollment target sits among peer trials
300 5th of 20 higher than 16 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
XACT ACE Observational Registry
RECRUITING
-
Perioperative Risk Study
ACTIVE NOT RECRUITING · NA
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI